Bill > SB43

This bill establishes a program within the Louisiana Department of Health to facilitate clinical studies on psychedelic-assisted therapy, which involves administering psychedelic medications like psilocybin or ibogaine in a controlled setting alongside psychotherapy. The program aims to explore the use of this therapy for conditions such as opioid use disorders, co-occurring substance use disorders, and treatment-resistant neurological or mental health issues. To participate, academic health centers must meet strict requirements, including having an FDA investigational new drug application, conducting studies at affiliated hospitals or clinics, maintaining necessary drug enforcement registrations, and obtaining Institutional Review Board approval. The studies must also have detailed protocols covering patient eligibility, informed consent, data security, drug administration plans, safety monitoring, and psychotherapy guidelines. The bill also outlines how human service districts and authorities will identify eligible patients, allows parishes to use opioid settlement funds for enrollment, and permits the department to seek additional funding. Participating centers will submit progress reports annually, and the department will compile a report for the legislature.

Health and Social Services

https://www.legis.la.gov/legis/BillInfo.aspx?s=26rs&b=SB43&sbi=y